ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting

    Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort

    Zulema Rosales Rosado1,2, Judit Font Urgelles1, Pia Mercedes Lois1, Cristina Vadillo Font1, Dalifer Freites Núñez2, Isabel Hernández-Rodríguez1, Juan A Jover Jover1 and Lydia A Alcazar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
  • Abstract Number: 603 • 2018 ACR/ARHP Annual Meeting

    Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation

    Gyanendra Pokharel1, Rob Deardon1, Sindhu Johnson2, George A. Tomlinson3 and Glen Hazlewood4, 1Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, 2Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 3Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…
  • Abstract Number: 2522 • 2018 ACR/ARHP Annual Meeting

    Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

    Stanley Cohen1, Niklas Czeloth2, Eric Lee3, Piotr A. Klimiuk4, Nuala Peter5 and Girish Jayadeva2, 1Metroplex Clinical Research Center, Dallas, TX, 2Boehringer Ingelheim, Ingelheim a.R., Germany, Ingelheim, Germany, 3Inland Rheumatology, Upland, CA, 4Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, Poland, 5Boehringer Ingelheim, Biberach a.d.R., Germany, Ingelheim a.R., Germany

    Background/Purpose: Clinical equivalence of BI 695501 to the adalimumab RP has been shown in pts with moderately-to-severely active RA in the Phase III VOLTAIRE®-RA study…
  • Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting

    Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database

    Elliot Hepworth1, Mohammad Movahedi2, Emmanouil Rampakakis3, Reza Mirza1, Arthur Lau4, Angela Cesta5, Janet E. Pope6 and Claire Bombardier7, 1Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3JSS Medical Research, Montreal, QC, Canada, 450 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
  • Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting

    Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)

    Paula Fortea-Gordo1, Laura Nuño2, Alejandro Villalba2, Diana Peiteado3, Irene Monjo4, Paloma Sanchez-Mateos5, Amaya Puig-Kröger6, Alejandro Balsa1 and Maria Eugenia Miranda-Carus1, 1Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, 2Rheumatology, La Paz University Hospital, Madrid, Spain, 3Hospital Universitario La Paz, Madrid, Spain, 4Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 5Immunology, Hospital Gregorio Marañon, Madrid, Spain, 6Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain

    Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
  • Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan

    Song-Chou Hsieh1, Yi-Hsing Chen2, Wei-Sheng Chen3, Wen-Chan Tsai4, Jui-Chieh Hu5, Hsiang-Cheng Chen6, Jack Mardekian7 and Chacun Lai8, 1National Taiwan University Hospital, Taipei, Taiwan, 2Taichung Veterans General Hospital, Taichung City, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 6National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, 7Pfizer Global Biometrics & Data Management, NY, NY, 8Pfizer PFE Limited, New Taipei, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
  • Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting

    Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells

    Judith Ashouri1, Lih-Yun Hsu1, Dmitry Rychkov2, Marina Sirota2, Lisa Lattanza3, Eric Hansen3, Julie Zikherman1 and Arthur Weiss1, 1Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, 3Orthopedic Surgery, University of California, San Francisco, San Francisco, CA

    Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
  • Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting

    Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events

    Caitrin Coffey1, Michael Richter1, Cynthia S. Crowson2, Matthew J. Koster3, Kenneth J. Warrington4 and Ashima Makol3, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
  • Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting

    Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program

    Stanley Cohen1, Yoshiya Tanaka2, Xavier Mariette3, Jeffrey R. Curtis4, Eun Bong Lee5, Peter Nash6, Kevin Winthrop7, Christina Charles-Schoeman8, Lisy Wang9, Connie Chen10, Kenneth Kwok10, Pinaki Biswas10, Andrea Shapiro11, Ann Madsen10 and Jürgen Wollenhaupt12, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Paris-Sud University, Le Kremlin Bicêtre, France, 4University of Alabama at Birmingham, Birmingham, AL, 5Seoul National University, Seoul, Korea, Republic of (South), 6University of Queensland, Brisbane, Australia, 7Oregon Health and Science University, Portland, OR, 8University of California, Los Angeles, CA, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY, 11Pfizer Inc, Peapack, NJ, 12Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
  • Abstract Number: 43 • 2018 ACR/ARHP Annual Meeting

    Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice

    Jie An1, Bhanupriya Madarampalli2, Xizhang Sun2, Lena Tanaka3, Erika H. Noss2, Joshua Woodward4, Tomikazu Sasaki5 and Keith B. Elkon6, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, University of Washington, Seattle, WA, 3Medicine/Rheumatology, University of Washington, Seattle, WA, 4Department of Microbiology, University of Washington, Seattle, WA, 5Department of Chemistry, University of Washington, Seattle, WA, 6University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease affecting ~1% of the world population and can lead to permanent joint damage and severe…
  • Abstract Number: 987 • 2018 ACR/ARHP Annual Meeting

    CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis

    Kuninobu Wakabayashi, Takeo Isozaki, Shinichiro Nishimi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

    Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is produced by a variety of cell types. By interacting with C-C chemokine receptor…
  • Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting

    Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model

    Kotona Furuyama1, Yuya Kondo1, Masaru Shimizu2, Iizuka Akira1, Masahiro Yokosawa1, Seiji Segawa1, Hiroto Tsuboi1, Isao Matsumoto1 and Takayuki Sumida1, 1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
  • Abstract Number: 1073 • 2018 ACR/ARHP Annual Meeting

    Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis

    Kazuhisa Nozawa1, Takuya Hirai2, Hiroshi Tsushima2, Ken Yamaji3, Naoto Tamura3 and Iwao Sekigawa4, 12-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, 2Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 3Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan

    Background/Purpose: Aberrant angiogenesis has been considered as one of important factors for pathogenesis of rheumatoid arthritis (RA). Several angiogenetic mediators are reported to be massively…
  • Abstract Number: 50 • 2018 ACR/ARHP Annual Meeting

    Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis

    Chrong-Reen Wang1, Shih-Yao Chen2, Yu-Ting Lo3, Yu-Chi Chou4, Ming-Fei Liu1, Chao-Liang Wu5 and Ai-Li Shiau3, 1Internal Medicine, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan, 2Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, 3Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, 4Core Facility for Manipulation of Gene Function, Academia Sinica, Taipei, Taiwan, 5Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan

    Background/Purpose: Aberrantly higher expression of long non-coding RNAs (lncRNAs) in synovial fibroblasts (SFs) plays pathogenic roles in rheumatoid joint. Studying the effects on knocking down…
  • Abstract Number: 1076 • 2018 ACR/ARHP Annual Meeting

    Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis

    Mingyo Kim, Hyun Min Jeon, Hae Sook Noh, Sang Mi Yi and Sang-Il Lee, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea, Republic of (South)

    Background/Purpose: The C2 domain is a Ca2+-dependent membrane-targeting motif found in many cellular proteins involved in signal transduction or inflammatory pathway. However, the effects of…
  • « Previous Page
  • 1
  • …
  • 169
  • 170
  • 171
  • 172
  • 173
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology